Earnings

Bristol Myers Squibb Announces Two-Year Results From Its Phase 3 POETYK PSA-2 Study Showing Durable Efficacy And A Consistent Safety Profile For Sotyktu In Adults With Active Psoriatic Arthritis; Data Build On The Proven Efficacy And Safety Of Sotyktu

Sep 17, 2026 · 07:12 AM ET· updated 1h ago

These data are being presented at the Congress of Clinical Rheumatology - West (CCR-West) in Huntington Beach, California, taking place September 17-20, 2026.Among patients who entered the OLE, Sotyktu demonstrated

Why It Matters

Bristol Myers tested a medicine called Sotyktu for joint pain over two years. The medicine kept working well and stayed safe, which is good news for the company.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BMY63.72

+0.12 (+0.19%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.